Survivin - Prognostic tumor biomarker in human neoplasms - Review;Surwiwina - Czynnik prognostyczny w nowotworach u ludzi - Praca poglądowa

Ginekologia Polska

Volumn 83, Issue 7, 2012, Pages 537-540

  Waligórska Stachura, Joanna ^a   Jankowska, Anna ^a   Waśko, Ryszard ^a   Liebert, Wlodzimierz ^a   Biczysko, Maciej ^a   Czarnywojtek, Agata ^a   Baszko Błaszyk, Daria ^a   Shimek, Violet ^a   Ruchała, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Neoplasms; Survivin; Tumor biomarker

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

APOPTOSIS; CANCER STAGING; DISEASE COURSE; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS; REVIEW;

APOPTOSIS; DISEASE PROGRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865808800     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Tamm I, Wang Y, Sausville E, [et al.]. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax caspases, and anticancer drugs. Cancer Res. 1998, 58, 5315-20.
2. Ambrosini G, Adida C, Altieri A. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3, 917-921.
3. Altieri D. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003, 3, 46-54.
4. O'Connor D, Grossman D, Plescia J, [et at.]. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 2000, 97, 13103-13107.
5. Kawasaki H, Altieri D, Lu C, [et al.]. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58, 5071-5074.
6. Kaczmarek-Borowska B, Filip A, Wojcierowski J, [et al.]. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol. 2005, 43, 237-242.
7. Mita A, Mita M, Nawrocki S, [et al.]. Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics. Clin Cancer Res. 2008, 14, 5000-5005.
8. Ceballos-Cancino G, Espinosa M, Maldonado V, [et al.]. Regulation of mitochondrial Smac/ DIABLO-selective release by survivin. Oncogene. 2007, 26, 7569-7575.
9. Kanwar J, Shen W, Kanwar R, [et al.]. Effects of Survivin Antagonists on Growth of Established Tumors and B7-1 Immunogene Therapy. J Natl Cancer Inst. 2001, 93, 92-95.
10. Yamamoto H, Ngan C, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008, 99, 1709-1714.
11. Fukuda S, Pelus L. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006, 5, 1087-1098.
12. Mirza A, Wu Q, Wang L, [et al.]. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene. 2002, 22, 3645-3654.
13. Nakano J, Huang C, Liu D, [et al.]. The clinical significance of splice variants and subcellular localization of survivin in non-small cell lung cancers. Br J Cancer. 2008, 98, 1109-1117.
14. Caldas H, Honsey L, Altura R. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005, 4, 11.
15. Wasko R, Jankowska A, Waligorska-Stachura J, [et al.]. Coexpression of survivin and PCNA in pituitary tumors and normal pituitary. Neuroendocrinol Lett. 2009, 30, 477-481.
16. Jankowska A, Wasko R, Waligorska-Stachura, [et al.]. Survivin products in pituitary tumors. Neuroendocrinol Lett. 2008, 6, 1033-1037.
17. Altieri D. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003, 22, 8581-8589.
18. O'Connor D, Wall N, Porter A, [et al.]. A p34(cdc2) survival checkpoint in cancer. Cancer Cell. 2002, 2, 43-54.
19. Wall N, O'Connor D, Plescia J, [et al.]. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003, 63, 230-235.
20. Tanaka K, Iwamoto S, Gon G, [et al.]. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000, 6, 127-134.
21. Zaffaroni N, Daidone M. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat. 2002, 5, 65-72.
22. Tran J, Master Z, Yu J, [et al.]. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA. 2002, 99, 4349-4354.
23. Swana H, Grossman D, Anthony J, [et al.]. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999, 341, 452-453.
24. Deguchi M, Shiraki K, Inoue H, [et al.]. Expression of survivin during liver regeneration. Biochem Biophys Res Commun. 2002, 297, 59-64.
25. Chiou S, Moon W, Jones M, [et al.]. Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem Biophys Res Commun. 2003, 305, 374-379.
26. Singh M, Bleile M, Shrover A, [et al.]. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Immunohistochem Mol Morphol. 2004, 12, 296-304.
27. Kim H, Shiraki K, Park S. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res. 2002, 22, 805-808.
28. Moon W, Tarnawski A. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Anticancer Res. 2003, 117, 738-744.
29. Ding Y, Prieto V, Zhang P, [at al.]. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer. 2006, 106, 1123-1129.
30. Sasaki T, Lopes M, Hankins G, [et al.]. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol. 2002, 104, 105-109.
31. Cong X, Han Z. Survivin and leukemia. Int J Hematol. 2004, 80, 232-238.
32. Nowak-Markwitz E, Puła B, Szajnik M, [et al.]. Expression of survivin, SDF-1 and CXCR4 on tumor cells in ovarian cancer. Ginekol Pol. 2010, 81, 674-677.
33. Fields A, Cotsonis G, Sexton D, [et al.]. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004, 17, 1378-1385.
34. Shinohara E, Gonzalez A, Massion P, [et al.]. Nuclear survivin predicts recurrence and poor survival in patients with resected non-small cell lung carcinoma. Cancer. 2005, 103, 1685-1692.
35. Cohen C, Lohmann C, Cotsonis G, [et al.]. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol. 2003, 16, 574-583.
36. Mahotka C, Wenzel M, Springer E, [et al.]. Survivin-ΔEx3 and survivin-2b: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999, 12, 59, 6097.
37. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer. 2005, 92, 212-216.
38. Krieg A, Mahotka C, Krieg T, [et al.]. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002, 86, 737-743.
39. Shapiro G. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006, 24, 1770-1783.
40. Jagat J, Shen W, Kanwar R, [et al.]. Effects of survivin antagonists on growth of established tumors and b7-1 immunogene therapy. J Natl Cancer Inst. 2001, 93, 1541-1552.
41. Doolittle H, Morel A, Talbot D, [et al.]. Survivin-directed anticancer therapies -a review of preclinical data and early-phase Clinical Trials. EurOncol. 2010, 6, 10-14.